Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extended immunotherapy shows promise for tough prostate cancer

NCT ID NCT05806814

Recruiting now Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Mar 22, 2026 · Last updated May 21, 2026 · Updated 8 times

Summary

This early-phase study tests whether giving an extended course of Sipuleucel-T (an immunotherapy) can strengthen the immune system's attack on prostate cancer cells in men with metastatic castration-resistant prostate cancer. About 13 participants will receive three infusions over 12-14 weeks. The goal is to see if this longer treatment is feasible and boosts immune responses against the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center

    RECRUITING

    Oklahoma City, Oklahoma, 73114, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)